After Hours Summary: MYL +2% on generic Concerta launch news... INNL down nearly 50% after FDA rejected its XARACOLL applicationAfter Hours Gainers:
- MYL +2.2% (launches generic version of Janssen's Concerta tablets)
- NVDA +1.2 (edging higher in extended trade after recouping early losses and closing near highs)
- AG +1.2%, MBLY +1.0% (continued strength)
After Hours Losers:
- INNL -49.2% (light volume; Innocoll received FDA Refusal to File letter for XARACOLL - its product candidate for postsurgical pain treatment)
- GEVO -8.6% (announces 1-for-20 reverse stock split)